Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2011
Date:11/7/2011

t also on the longer-term commercial opportunities as we continue to develop this important product," continued Ms. Parshall.

"Although Kynamro is our flagship drug and will be the first systemic antisense drug to reach the market, our pipeline goes well beyond Kynamro.  Numerous drugs in our pipeline have demonstrated efficacy in early clinical studies and could represent significant commercial opportunities," continued Ms. Parshall. "The success of our drug discovery and development efforts is evident every quarter as we move our drugs closer to the market.  Already this year, we have initiated clinical studies on five drugs, reported encouraging data on our CRP drug and added new drugs into development to treat a wide variety of diseases.   We anticipate continuing this steady progress for the rest of the year and into 2012.

"Our business strategy is successful as evidenced by the growth of our partnered pipeline and the substantial cash from our partnering deals.  We benefit financially both in the near-term and long-term, from upfront fees, milestone payments, royalties and profit sharing payments and other types of commercial participation.  This year, we have earned $13 million in milestones and upfront payments from our partner, GSK, with the expansion of our collaboration to include a sixth target, initiation of clinical development on our TTR drug and identification of the next drug, ISIS-AATRx, to move into development.  This collaboration provides us with a knowledgeable partner and allows us to quickly expand our severe and rare disease franchise," concluded Ms. Parshall.  

Corporate and Drug Development Highlights

  • Dr. John Kastelein presented data from the mipomersen open-label extension study at the European Society of Cardiology Congress 2011.  These data, in patients who have been treated with mipomersen for greater than one year, demonstrated sustained reductions in
    '/>"/>

  • SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
    2. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
    3. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
    4. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
    5. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
    6. Cambrex Reports Third Quarter 2011 Results
    7. Dyadic International Reports 2011 Third Quarter Financial Results
    8. Rochester Medical Reports Fourth Quarter and Fiscal Year End Results
    9. Mettler-Toledo International Inc. Reports Third Quarter 2011 Results
    10. IRIDEX Reports 2011 Third Quarter and Nine-Month Results
    11. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
    (Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
    (Date:12/19/2014)... LONDON , December 19, 2014 ... authentication services in the World announced the appointment of ... Anthony R. Vonsée, as Chief Channels and Partner Officer. ... Datanomic since 2004 through to its acquisition by Oracle ... Development Director at Geneva and ...
    Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4
    ... INDIANAPOLIS, April 29, 2011 KPaul Properties LLC today ... Women,s Business Enterprise Division, has awarded it the coveted ... a year after KPaul was awarded the INC Magazine ... After receiving the news, founder and president ...
    ... Mich., April 29, 2011 Phil Hagerman, president and CEO ... Thornton Leader & Innovator of the Year. The ... University, which co-sponsors the annual award along with Grant Thornton ... and Technology Report. Hagerman was chosen from among 45 ...
    Cached Medicine Technology:Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 2Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 3
    (Date:12/22/2014)... Only weeks following the announcement that Henderson, Nevada ... a battery manufacturer create 29 well-paying jobs in Mojave ... launching in Henderson to deliver yet another win ... sector is going to build a stronger middle class ... works with small businesses that rely on middle class ...
    (Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
    (Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
    (Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
    (Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
    Breaking Medicine News(10 mins):Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
    ... discovered an accomplice in breast cancer a master control ... reactions orchestrated by a cancer-causing gene (or oncogene) named Wnt1. ... back-to-back papers featured on the cover of the August 15 ... about the regulation of a Wnt oncogene," explains lead author ...
    ... By Jenifer Goodwin HealthDay Reporter , ... mistakes, admitting the error, saying "I,m sorry" and offering ... lawsuits, new research shows. In 2001, University ... workers to report medical mistakes. The program included a ...
    ... Supports (CLASS) Act a largely overlooked component of the ... potential to transform long-term care financing in the United States ... latest issue of Public Policy & Aging Report ... The SCAN Foundation , this installment of PPAR ...
    ... This release is available in French . ... boys with low parental monitoring are more likely to befriend ... to a new study published in the journal Addictive ... de Montral and Sainte-Justine University Hospital Research Center found that ...
    ... fellow Amy Speed-Andrews has examined how a specialized Iyengar yoga ... who have completed treatment, makes a difference in their recovery. ... to fill out a questionnaire about their physical and mental ... yoga and again at the end. After analyzing the data ...
    ... are developing the first device able to transmit American ... just completing its initial field test by participants in ... "This is the first study of how deaf people ... project leader Eve Riskin, a UW professor of electrical ...
    Cached Medicine News:Health News:Researchers identify breast cancer culprits 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 3Health News:CLASS Act analysis reveals America's long-term care future 2Health News:Heavy drug-use among bad boys curbed by parental monitoring and peers 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 3
    ... Delivery System (CDS) facilitates the ... the Aescula LV Left-Heart Lead. ... patented coronary sinus curve that ... access to the coronary sinus ...
    ... PCS2 system is Haemonetics ... collection of plasma and ... the collection of "jumbo" ... platelet-poor plasma with optional ...
    Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
    ... provides quick, convenient, repetitive dispensing for ... have a polyethylene plunger and a ... use with most reagents. Application: ... separate volumes can be selected for ...
    Medicine Products: